IGF1 and non-small cell lung carcinoma: Further on, miR-486, which is substantially downregulated in non-small cell lung cancer, has been demonstrated to alter migration and proliferation via the IGF-1/PI3K/Akt pathway, by targeting IGF1, IGR1R, and p85 (97, 98).